Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1989 Apr;83(4):1349–1355. doi: 10.1172/JCI114022

Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium.

J A Delmez 1, C Tindira 1, P Grooms 1, A Dusso 1, D W Windus 1, E Slatopolsky 1
PMCID: PMC303828  PMID: 2703535

Abstract

Numerous in vitro studies in experimental animals have demonstrated a direct suppressive effect of 1,25-dihydroxyvitamin D (1,25(OH)2D) on parathyroid hormone (PTH) synthesis. We therefore sought to determine whether such an effect could be demonstrated in uremic patients undergoing maneuvers designed to avoid changes in serum calcium concentrations. In addition, the response of the parathyroid gland in patients undergoing hypercalcemic suppression (protocol I) and hypocalcemic stimulation (protocol II) before and after 2 wk of intravenous 1,25(OH)2D was evaluated. In those enlisted in protocol I, PTH values fell from 375 +/- 66 to 294 +/- 50 pg (P less than 0.01) after 1,25(OH)2D administration. During hypercalcemic suppression, the "set point" (PTH max + PTH min/2) for PTH suppression by calcium fell from 5.24 +/- 0.14 to 5.06 +/- 0.15 mg/dl (P less than 0.05) with 1,25(OH)2D. A similar decline in PTH levels after giving intravenous 1,25(OH)2D was noted in protocol II patients. During hypocalcemic stimulation, the parathyroid response was attenuated by 1,25(OH)2D. We conclude that intravenous 1,25(OH)2D directly suppresses PTH secretion in uremic patients. This suppression, in part, appears to be due to increased sensitivity of the gland to ambient calcium levels.

Full text

PDF
1349

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berl T., Berns A. S., Hufer W. E., Hammill K., Alfrey A. C., Arnaud C. D., Schrier R. W. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann Intern Med. 1978 Jun;88(6):774–780. doi: 10.7326/0003-4819-88-6-774. [DOI] [PubMed] [Google Scholar]
  2. Brown E. M., Brennan M. F., Hurwitz S., Windeck R., Marx S. J., Spiegel A. M., Koehler J. O., Gardner D. G., Aurbach G. D. Dispersed cells prepared from human parathyroid glands: distinct calcium sensitivity of adenomas vs. primary hyperplasia. J Clin Endocrinol Metab. 1978 Feb;46(2):267–275. doi: 10.1210/jcem-46-2-267. [DOI] [PubMed] [Google Scholar]
  3. Brown E. M., Wilson R. E., Eastman R. C., Pallotta J., Marynick S. P. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab. 1982 Jan;54(1):172–179. doi: 10.1210/jcem-54-1-172. [DOI] [PubMed] [Google Scholar]
  4. Brumbaugh P. F., Hughes M. R., Haussler M. R. Cytoplasmic and nuclear binding components for 1alpha25-dihydroxyvitamin D3 in chick parathyroid glands. Proc Natl Acad Sci U S A. 1975 Dec;72(12):4871–4875. doi: 10.1073/pnas.72.12.4871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cantley L. K., Russell J., Lettieri D., Sherwood L. M. 1,25-Dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture. Endocrinology. 1985 Nov;117(5):2114–2119. doi: 10.1210/endo-117-5-2114. [DOI] [PubMed] [Google Scholar]
  6. Chan Y. L., McKay C., Dye E., Slatopolsky E. The effect of 1,25 dihydroxycholecalciferol on parathyroid hormone secretion by monolayer cultures of bovine parathyroid cells. Calcif Tissue Int. 1986 Jan;38(1):27–32. doi: 10.1007/BF02556591. [DOI] [PubMed] [Google Scholar]
  7. Chertow B. S., Baylink D. J., Wergedal J. E., Su M. H., Norman A. W. Decrease in serum immunoreactive parathyroid hormone in rats and in parathyroid hormone secretion in vitro by 1,25-dihydroxycholecalciferol. J Clin Invest. 1975 Sep;56(3):668–678. doi: 10.1172/JCI108137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cheung A. K., Manolagas S. C., Catherwood B. D., Mosely C. A., Jr, Mitas J. A., 2nd, Blantz R. C., Deftos L. J. Determinants of serum 1,25(OH)2D levels in renal disease. Kidney Int. 1983 Jul;24(1):104–109. doi: 10.1038/ki.1983.131. [DOI] [PubMed] [Google Scholar]
  9. Clarkson E. M., McDonald S. J., De Wardener H. E. The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin Sci. 1966 Jun;30(3):425–438. [PubMed] [Google Scholar]
  10. Delmez J. A., Dougan C. S., Gearing B. K., Rothstein M., Windus D. W., Rapp N., Slatopolsky E. The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int. 1987 Mar;31(3):795–799. doi: 10.1038/ki.1987.68. [DOI] [PubMed] [Google Scholar]
  11. Henry H. L., Norman A. W. Studies on the mechanism of action of calciferol VII. Localization of 1,25-dihydroxy-vitamin D3 in chick parathyroid glands. Biochem Biophys Res Commun. 1975 Feb 17;62(4):781–788. doi: 10.1016/0006-291x(75)90391-5. [DOI] [PubMed] [Google Scholar]
  12. Korkor A. B. Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med. 1987 Jun 18;316(25):1573–1577. doi: 10.1056/NEJM198706183162504. [DOI] [PubMed] [Google Scholar]
  13. Lopez-Hilker S., Galceran T., Chan Y. L., Rapp N., Martin K. J., Slatopolsky E. Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. J Clin Invest. 1986 Oct;78(4):1097–1102. doi: 10.1172/JCI112666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Madsen S., Olgaard K., Ladefoged J. Suppressive effect of 1,25-dihydroxyvitamin D3 on circulating parathyroid hormone in acute renal failure. J Clin Endocrinol Metab. 1981 Oct;53(4):823–827. doi: 10.1210/jcem-53-4-823. [DOI] [PubMed] [Google Scholar]
  15. Makoff D. L., Gordon A., Franklin S. S., Gerstein A. R., Maxwell M. H. Chronic calcium carbonate therapy in uremia. Arch Intern Med. 1969 Jan;123(1):15–21. [PubMed] [Google Scholar]
  16. Martin K. J., Hruska K. A., Lewis J., Anderson C., Slatopolsky E. The renal handling of parathyroid hormone. Role of peritubular uptake and glomerular filtration. J Clin Invest. 1977 Oct;60(4):808–814. doi: 10.1172/JCI108834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mason R. S., Lissner D., Wilkinson M., Posen S. Vitamin D metabolites and their relationship to azotaemic osteodystrophy. Clin Endocrinol (Oxf) 1980 Oct;13(4):375–385. doi: 10.1111/j.1365-2265.1980.tb03399.x. [DOI] [PubMed] [Google Scholar]
  18. Merke J., Hügel U., Zlotkowski A., Szabó A., Bommer J., Mall G., Ritz E. Diminished parathyroid 1,25(OH)2D3 receptors in experimental uremia. Kidney Int. 1987 Sep;32(3):350–353. doi: 10.1038/ki.1987.216. [DOI] [PubMed] [Google Scholar]
  19. Meyrier A., Marsac J., Richet G. The influence of a high calcium carbonate intake on bone disease in patients undergoing hemodialysis. Kidney Int. 1973 Aug;4(2):146–153. doi: 10.1038/ki.1973.93. [DOI] [PubMed] [Google Scholar]
  20. Moriniere P., Roussel A., Tahiri Y., de Fremont J. F., Maurel G., Jaudon M. C., Gueris J., Fournier A. Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism. Proc Eur Dial Transplant Assoc. 1983;19:784–787. [PubMed] [Google Scholar]
  21. Morrissey J., Rothstein M., Mayor G., Slatopolsky E. Suppression of parathyroid hormone secretion by aluminum. Kidney Int. 1983 May;23(5):699–704. doi: 10.1038/ki.1983.81. [DOI] [PubMed] [Google Scholar]
  22. Oldham S. B., Smith R., Hartenbower D. L., Henry H. L., Norman A. W., Coburn J. W. The acute effects of 1,25-dihydroxycholecalciferol on serum immunoreactive parathyroid hormone in the dog. Endocrinology. 1979 Jan;104(1):248–254. doi: 10.1210/endo-104-1-248. [DOI] [PubMed] [Google Scholar]
  23. Reinhardt T. A., Horst R. L., Orf J. W., Hollis B. W. A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies. J Clin Endocrinol Metab. 1984 Jan;58(1):91–98. doi: 10.1210/jcem-58-1-91. [DOI] [PubMed] [Google Scholar]
  24. Russell J., Lettieri D., Sherwood L. M. Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene. Endocrinology. 1986 Dec;119(6):2864–2866. doi: 10.1210/endo-119-6-2864. [DOI] [PubMed] [Google Scholar]
  25. Sherman R. A., Bialy G. B., Gazinski B., Bernholc A. S., Eisinger R. P. The effect of dialysate calcium levels on blood pressure during hemodialysis. Am J Kidney Dis. 1986 Oct;8(4):244–247. doi: 10.1016/s0272-6386(86)80033-6. [DOI] [PubMed] [Google Scholar]
  26. Silver J., Naveh-Many T., Mayer H., Schmelzer H. J., Popovtzer M. M. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest. 1986 Nov;78(5):1296–1301. doi: 10.1172/JCI112714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Silver J., Russell J., Sherwood L. M. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci U S A. 1985 Jun;82(12):4270–4273. doi: 10.1073/pnas.82.12.4270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Slatopolsky E., Weerts C., Lopez-Hilker S., Norwood K., Zink M., Windus D., Delmez J. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med. 1986 Jul 17;315(3):157–161. doi: 10.1056/NEJM198607173150304. [DOI] [PubMed] [Google Scholar]
  29. Slatopolsky E., Weerts C., Thielan J., Horst R., Harter H., Martin K. J. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest. 1984 Dec;74(6):2136–2143. doi: 10.1172/JCI111639. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES